Comparative In Vitro Activity of Tigecycline and Nine Other Antibiotics Against Gram-Negative Bacterial Isolates, Including ESBL-Producing Strains

REFERENCES

• Zhanel GG, Homenuik K, Nichol K, Noreddin A, Vercaigne L, Embil J, et al. The glycylcyclines: a comparative review with the tetracyclines. Drugs 2004; 64: 63–88.
   PubMed Web of Science ®Google Scholar
• Doan TL, Fung HB, Mehta D, Riska PF. Tigecycline: a gly-cylcycline antimicrobial agent. Clin Ther 2006; 28: 1079–106.
   PubMed Web of Science ®Google Scholar
• Bauer G, Berens C, Projan SJ, Hillen W. Comparison of tetracycline and tigecycline binding to ribosomes mapped by di-methylsulphate and drug- directed Fe2' cleavage of 16S rRNA. J Antimicrob Chemother 2004; 53: 592–9
   PubMed Web of Science ®Google Scholar
• Bergeron J, Ammirati M, Danley D, Janes L, Noricia M, Retsema J, et al. Glycylcyclines bind to the high- affinity tetracy-cline ribosomal binding site and evade Tet(M)- and Tet(0)- medi-ated ribosomal protection. Antimicrob Agents Chemother 1996; 40: 2226–8.
   PubMed Web of Science ®Google Scholar
• Dean CR, Visalli MA, Projan SJ, Sum PE, Bradford PA. Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PA01. Antimicrob Agents Chemother 2003; 47: 972–8.
   PubMed Web of Science ®Google Scholar
• Ruzin A, Keeney D, Bradford PA. AcrAB efflux pump plays a role in decreased susceptibility to tigecycline in Morganella morganii. Antimicrob Agents Chemother 2005; 49: 791–3.
   PubMed Web of Science ®Google Scholar
• Hawkey P, Finch R. Tigecycline: in vitro performance of as a predictor of clinical efficacy. Clin Microbiol Infect 2007; 13: 354–62.
   PubMed Web of Science ®Google Scholar
• Ruzin A, Keeney D, Bradford PA. AdeABC multidrug efflux pump is associated with decreased susceptibility to tigecycline in Acinetobacter calcoaceticus—Acinetobacter baumannii com-plex. J Antimicrob Chemother 2007; 59: 1001–4.
   PubMed Web of Science ®Google Scholar
• Yang W, Moore IF, Koteva KP, Bareich DC, Hughes DW, Wright GD. TetX is a flavin-dependent monooxygenase conferring resistance to tetracycline antibiotics. J Biol Chem 2004; 279: 52346–52.
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial susceptibility Testing: Seventeenth Informational supplement, M 100-S17. CLSI 2007, Wayne, PA, USA
   Google Scholar
• Weyth Pharmaceutical Inc. Tygacil Product Insert. Philadelphia, PA, USA.
   Google Scholar
• Cao V, Lambert T, Courvalin P. ColEl-like plasmid pIP843 of Klebsiella pneumoniae encoding extended-spectrum -lactamase CTX-M-17. Antimicrob Agents Chemother 2002; 46: 1212–7.
   PubMed Web of Science ®Google Scholar
• European Committee on Antimicrobial Susceptibility Testing (EUCAST) Steering committee. EUCAST Technical Note on tigecycline. Clin Microbiol Infect 2006; 12: 1147–9.
   Google Scholar
• Cosgrove SE. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay and health care costs. Clin Infect Dis 2006; 42 Suppl 2: S82–9.
   PubMed Web of Science ®Google Scholar
• Jamal W, Rotimi VO, Khodakhast F, Saleem R, Pazhoor A, Al Hashem G. Prevalence of extended spectrum beta-lacta-mases (ESBL) in Enterobacteriaceae, Pseudomonas and Stenotrophomonas as determined by the VITEK 2 and Etest sys-tems in a Kuwait Teaching Hospital. Med Princ Pract 2005; 14: 325–31.
   PubMed Web of Science ®Google Scholar
• Mokaddas EM, Abdulla, SS, Rotimi VO. The technical aspects and clinical significance of detecting extended-spectrum -lactamase-producing Enterobacteriaceae at a tertiary-care hospital in Kuwait. J Chemother 2008; 20 (4): 445–451.
   PubMed Web of Science ®Google Scholar
• Hong T, Moland ES, Abdalhamid B, Hanson ND, Wang J, Solan C, et al. Escherichia coil: development of carbapenem resistance during therapy. Clin Infect Dis 2005; 40: e48-6.
   PubMed Web of Science ®Google Scholar
• Morosini MI, Garcia-Castillo M, Coque TM, Valverde A, Novais A, Loza E, et al. Antibiotic coresistance in extended spec-trum 8-lactamase-producing Enterobacteriaceae and in vitro activity of tigecycline. Antimicrob Agents Chemother 2006; 50: 2695–9.
   Google Scholar
• Cheng N, Hsueh P, Liu Y, Shyr J, Huang W, Teng L, et al. In vitro activities of tigecycline, ertapenem, isepamicin and other antimicrobial agents against clinically isolated organisms in Taiwan. Microb Drug Resist 2005; 11: 330–41.
   PubMed Web of Science ®Google Scholar
• Reinert RR, Low DE, Rossi F, Zhang X, Wattal C, Dowz-icky MJ. Antimicrobial susceptibility among organisms from Asia/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline. J Antimi-crob Chemother 2007; 60: 1018–29.
   PubMed Web of Science ®Google Scholar
• Tan T-Y, Ng lily SY. Susceptibility of multi-drug resistant Gram-negative bacilli in Singapore to tigecycline as tested by agar dilution. Ann Acad Med Singapore 2007; 36: 36: 807–810.
   Google Scholar
• Pitout JDD, Le P, Church DL, Gregson DB, Laupland KB. Antimicrobial susceptibility of well-characterised multiresistant CTX-M-producing Escherichia coil: failure of automated systems to detect resistance to piperacillin/tazobactam. Int J Antimicrob Agents 2008; 32: 333–338.
   PubMed Web of Science ®Google Scholar
• Rotimi V, Jamal W, Salama MI, AL-Din K, Dehrab N. Role of tigecycline in the control of carbapenem-resistant Acineto-bacter baumannii infections in an Intensive Care Unit, Kuwait, Abstract # P795, Proceedings of the 18th ECCMID, Barcelona, 2008, page 92
   Google Scholar
• Pachon-Ibanez ME, Jimenez-Mejias ME, Pichardo C, Llanos AC, Pachon J. Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem. Antimicrob Agents Chemother 2004; 49: 4479–81
   Web of Science ®Google Scholar
• Lolans K, Rice TW, Munoz-Price LS, Quinn JP. Multicity outbreak of carbapenem-resistant Acinetobacter baumannii iso-lates producing the carbapenemase OXA-40. Antimicrob Agents Chemother 2006; 50: 2941–45.
   PubMed Web of Science ®Google Scholar
• Navon-Venezia S, Leavitt A, Carmeli Y. High tigecycline resistance in multidrug -resistant Acinetobacter baumannii. J Antimicrob Chemother 2007; 59: 772–4.
   PubMed Web of Science ®Google Scholar
• Peleg AY, Potoski BA, Rea R, Adams J, Sethi J, Capi-tano B, et al. Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J Antimicrob Chemother 2007; 59: 128–31.
   PubMed Web of Science ®Google Scholar
• Rotimi VO, Mokaddas EM, Jamal WY, Khodakhast FB, Verghese TL, Sanyal SC. Susceptibility of 497 clinical isolates of Gram-negative anaerobes to Trovafloxacin and eight other an-tibiotics. J Chemother 1999; 11: 349–56.
   PubMed Web of Science ®Google Scholar
• Rotimi VO, Khoursheed M, Brazier JS, Jamal WY, Kho-dakhast FB. Bacteroides species highly resistant to metronida-zole: an emerging clinical problem? Clin Microbiol Infect 1999; 5: 166-9.
   Google Scholar
• Phillips OA, Rotimi VO, Jamal WY, Shahin M, Verghese TL. Comparative in vitro activity of PH-027 versus linezolid and other anti-anaerobic antimicrobials against clinical isolates of Clostridium difficile and other anaerobic bacteria. J Chemother 2003; 15: 61–5.
   Google Scholar
• Bethu C, Culebras E, Gomez M, Rodriguez-Avial I, Picazo JJ. In vitro activity of tigecycline against Bacteroides species. J Antimicrob Chemother 2005; 56: 349–52.
   PubMed Web of Science ®Google Scholar
• Snydman DR, Jacobus NV, McDermott LA, Ruthazer R, Golan Y, Goldstein EJ, et al. National survey on the susceptibil-ity of Bacteroides fragilis group: report and analysis of trends in the United States from 1997-2004. Antimicrob Agents Chemother 2007; 51: 1649–55.
   PubMed Web of Science ®Google Scholar
• Jacobus NV, McDermott LA, Ruthazer R, Snydman DR. In vitro activities of tigecycline against the Bacteroides fragilis group. Antimicrob Agents Chemother 2004; 48: 1034–6.
   PubMed Web of Science ®Google Scholar
• Bouchillon SK, Hoban DJ, Johnson BM, Johnson A, Hsi-ung A, Dowzicky MJ: Tigecycline Evaluation and Surveillance Trial (TEST) Group. In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program 2004): Diagn Microbiol Infect Dis. 2005; 52: 173–9.
   Google Scholar
• Livermore DI. Tigecycline: what it is, and where should it be used? J Antimicrob Chemother 2005; 56: 611–4.
   PubMed Web of Science ®Google Scholar